Okay, I need to share something that just made me genuinely excited about cancer research. And I don't say that lightly.
There's a new study out from researchers at UCL and UCLH that's making waves in the cancer research world. They're testing an immunotherapy drug called pembrolizumab — given before surgery — and the results are honestly remarkable.
Here's the deal: 32 patients with a specific genetic type of bowel cancer (MMR deficient/MSI-high, if you want to get technical) received about nine weeks of immunotherapy before their planned surgery. No chemotherapy first. No waiting around. Just this targeted immune therapy to prime their bodies to fight back.
And then? They tracked these patients for 33 months.
Zero. Recurrences.
Not one single patient saw their cancer come back. Not even in the patients who still had tiny traces of cancer remaining after treatment — those residual cells just... sat there. Didn't grow. Didn't spread. Didn't do anything.
Compare that to the standard approach — surgery followed by chemo — where about 25% of patients typically see their cancer return within three years. That's a pretty staggering difference.
Now, I want to be careful here because this isn't a cure for all bowel cancer. This particular genetic profile shows up in roughly 10-15% of stage two and three bowel cancer cases. But here's what's so promising: we're talking about patients who historically had tougher odds, and this approach is giving them something that looks remarkably close to durable remission.
But the researchers didn't just stop at "wow, it worked!" They're trying to figure out why it worked so well — and more importantly, how to predict who will benefit most.
They developed personalized blood tests that can essentially look for traces of tumor DNA floating around in the bloodstream. The disappearance of that tumor DNA closely matched whether patients had zero detectable cancer remaining. Think about what that means: potentially being able to tell early on whether treatment is working, without waiting months for scans.
Dr. Kai-Keen Shiu, one of the lead researchers, put it this way: this could help doctors tailor treatment. Patients doing well might need less aggressive therapy. Patients at higher risk could get more intensive care, exactly when they need it.
Here's what really got me about this story. Bowel cancer is the fourth most common cancer in the UK, with around 44,000 new cases each year. And while we often talk about how outcomes are better when caught early (and they are — stage one has around 90% five-year survival), the reality is that not everyone is that lucky. Stage three drops to 65%, and stage four is only 10%.
So when something comes along that might meaningfully shift those numbers — especially for patients with harder-to-treat subtypes — it's worth paying attention.
Is this the final answer? No. This is a small trial (32 patients), and we always need to see results replicated in larger studies. But "zero recurrences after 33 months" is the kind of headline that makes researchers lean forward in their chairs and go, "Okay, we need to understand this better."
And honestly? That's exactly the kind of science I love writing about.